ACE2 and COVID-19: Based on the presence of the more severe symptoms manifested from patients infected by COVID-19 in the presence of pre-existing CVD, probably due to an increased secretion of ACE2, one of the proposed mechanisms of acute myocardial injury caused by SARS-CoV-2 infection and of the increased infectivity of patients with pre-existing CVD has been linked to ACE2 levels.